ZAI LAB LIMITED Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
ZAI LAB LIMITED (ZLAB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $52.50 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-26
- ZAI LAB LIMITED share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $52.50M, a 458.51% increase from fiscal 2024.
- ZAI LAB LIMITED share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $9.40M, a 53.69% decline from fiscal 2023.
- ZAI LAB LIMITED share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $20.30M, a 41.96% increase from fiscal 2022.
- ZAI LAB LIMITED share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $14.30M, a 91.61% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2025-12-31 | $52.50M 10-K · filed 2026-02-26 |
| 2024-12-31 | $9.40M 10-K · filed 2026-02-26 |
| 2023-12-31 | $20.30M 10-K · filed 2026-02-26 |
| 2022-12-31 | $14.30M 10-K · filed 2025-02-27 |
| 2021-12-31 | $170.40M 10-K · filed 2024-02-27 |
| 2020-12-31 | $64.80M 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |